Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2024 | Single agent chemotherapy in ET-refractory invasive lobular carcinoma

Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents findings from a study assessing single-agent chemotherapy in patients with metastatic invasive lobular breast cancer (mILC) pre-treated with endocrine therapy (ET). Capecitabine was found to be more efficacious than taxanes, warranting further research in this space. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.